A hydroxamic acid that specifically inhibits urease; it retards alkalinization of the urine caused by urease-producing bacteria and may inhibit bacterial growth. Used in the prevention and dissolution of uroliths, but in dogs causes a dose-related, reversible hemolytic anemia and blood dyscrasia. Abbreviated AHA.
| Systematic (IUPAC) name | |
|---|---|
| ethanehydroxamic acid | |
| Clinical data | |
| AHFS/Drugs.com | Consumer Drug Information |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 546-88-3 |
| ATC code | G04BX03 |
| PubChem | CID 1990 |
| DrugBank | DB00551 |
| ChemSpider | 1913 |
| UNII | 4RZ82L2GY5 |
| KEGG | D00220 |
| ChEBI | CHEBI:49029 |
| ChEMBL | CHEMBL734 |
| Chemical data | |
| Formula | C2H5NO2 |
| Mol. mass | 75.0666 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
|
Acetohydroxamic acid (also known as AHA or Lithostat) is a drug that is a potent and irreversible inhibitor of bacterial and plant urease usually used for urinary tract infections. The molecule is similar to urea but is not hydrolyzable by the urease enzyme (Fishbein and Carbone, 1965).
|
||||||||||||||||
| This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)